Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019

Matthew J. Jackson, Gregory Vaughan, Fred D. Ledley
doi: https://doi.org/10.1101/2023.06.01.23290833

Article Information

doi 
https://doi.org/10.1101/2023.06.01.23290833
History 
  • June 4, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Matthew J. Jackson1,
  2. Gregory Vaughan2 and
  3. Fred D. Ledley1,3,4,*
  1. 1Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, USA
  2. 2Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts, USA
  3. 3Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts, USA
  4. 4Department of Management, Bentley University, Waltham, Massachusetts, USA
  1. ↵*Corresponding author: Fred D. Ledley, Center for Integration of Science and Industry, Bentley University, Jennison Hall 144, 175 Forest Street, Waltham, MA 02452, fledley{at}bentley.edu, 781-891-2046.
Back to top
Posted June 04, 2023.
Download PDF
Data/Code
Email
Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019
Matthew J. Jackson, Gregory Vaughan, Fred D. Ledley
medRxiv 2023.06.01.23290833; doi: https://doi.org/10.1101/2023.06.01.23290833
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area